Protara Therapeutics, Inc. (TARA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone. My name is Jim, and I will be your conference operator today. At this time, I would like to welcome everyone to the Protara Therapeutics Lymphatic Mouth Formations KOL webinar. All lines have been placed on a mute to prevent any background noise. And please note that all questions for the Q&A discussion at the end should be entered into the chat box in the bottom left of our screen. And now, for opening remarks and introductions, I am pleased to turn the floor to our host, Senior Vice President of Investor Relations, Justine O'Malley. Welcome. Thank you, Jim. Good afternoon. Thank you all for joining us today for a review of Protara's Lymphatic Malformations Program. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. These statements represent our views as of today only and should not be relied upon as representing our views as of any subsequent date. Actual results may differ from our forward-looking statements due to various factors, including those described in the risk factors section of our most recent annual report and subsequently filed quarterly reports that are on file with the SEC. Except as required by law, we disclaim any obligation to update these statements, even if our views change. I will now turn the call over to Jesse Shepperman, co-founder, director, and chief executive officer. Thank you, Justine, and thank you all for joining us this afternoon. Good afternoon from the World Congress of the International Society for the Study of Vascular Anomalies, or ISFAs. We are excited to provide an overview of our lymphatic malformations program today, including a recap of our recent FDA engagements and our plans to submit a BLA in the second half of 2027 for TA...